myocarditis

in review 7 min read Updated 2026-10-22
myocarditis

Young patient, viral prodrome, infarct-like chest pain, raised troponin, non-coronary ST change → exclude ACS, then CMR confirms (oedema + LGE, Lake Louise). Most cases with chest pain and preserved LVEF recover with supportive care. Risk is set by LV dysfunction, HF, sustained VT, high-grade AV block or shock → admit, HF/arrhythmia therapy, and endomyocardial biopsy when histology changes treatment (giant cell, eosinophilic, sarcoid). No routine immunosuppression. Restrict exercise until remission (≥1 month); CMR within 6 months.

do not miss

Fulminant myocarditis (shock — early transfer to an MCS/biopsy centre), giant cell myocarditis (HF + VT or AV block, poor response in 1–2 weeks), ICI myocarditis (high-dose steroids within 24 h), and ACS masquerading as myocarditis.


mechanism → management

  • Injury phase (days): virus or trigger → myocyte necrosis → troponin, ST change, arrhythmia
  • Immune phase: T-cell and macrophage infiltration → oedema, contractile dysfunction → most resolve; persistent inflammation → inflammatory cardiomyopathy (~10% of DCM)
  • Scar phase: LGE = fibrosis → substrate for monomorphic VT years later, independent of LVEF → follow-up imaging and rhythm monitoring even after recovery
  • Exercise in the active phase → tachycardia-driven inflammation and arrhythmia → restriction until remission
  • Steroids help where the driver is autoimmune (giant cell, eosinophilic, sarcoid, ICI) — not in viral lymphocytic myocarditis with preserved function

recognition

presentationclues
infarct-like chest pain (>80%)young, often male; fever, GI or respiratory prodrome 1–2 weeks earlier; ST elevation in non-coronary distribution; troponin rise
heart failurenew LV dysfunction, often non-dilated early; HHV-6, giant cell, eosinophilic
arrhythmiaNSVT/VT (polymorphic when active, monomorphic when scarred); AV block → think sarcoid, giant cell, Lyme
sudden death / shockfulminant form
  • ECG normal in ~15%; ST elevation most common, then T-wave change, conduction block, low voltage
  • troponin and NT-proBNP; CRP raised in ~80% (normal doesn’t exclude)
  • echo: wall motion abnormality, increased wall thickness (oedema), effusion in up to 25%
  • ACS first — angiography or CT coronary angiography by pretest probability; a “normal coronaries” MI is not myocarditis until CMR says so → MINOCA
  • myopericarditis (pericarditis + troponin, normal LV) → treat as acute pericarditis; perimyocarditis = new LV dysfunction → this note

causes worth naming

causeclue
viral (enterovirus, adenovirus, parvovirus B19, HHV-6, influenza, SARS-CoV-2)commonest; presumed, not tested — no routine viral serology except HIV, hepatitis C, Lyme
vaccines (mRNA COVID-19, smallpox)days after vaccination; good mid-term outcome
immune checkpoint inhibitorsfirst weeks of therapy (median ~30 days), combination ICI; AV block, myositis, myasthenia overlap; mortality up to ~50%
drugsclozapine (0.1–5% of users), DRESS-associated hypersensitivity
eosinophilicperipheral eosinophilia (absent in ~25%), EGPA, hypereosinophilic syndrome, drug hypersensitivity; LV thrombus
giant cellyoung–middle aged, rapidly progressive HF, VT, AV block
sarcoidAV block, VT, extracardiac sarcoid → CMR + FDG-PET
systemic autoimmuneSLE, systemic sclerosis, myositis
LymeAV block in endemic area → antibiotics, temporary pacing

risk stratification and workup

riskfeaturesdisposition
highHF/shock, NYHA III–IV, cardiac arrest/syncope, sustained VT/VF, high-grade AV block, LVEF <40%, extensive LGEICU/CCU; MDT at referral centre; consider EMB
intermediatenew dyspnoea, NSVT, persistent or relapsing troponin, LVEF 41–49% or WMA, preserved LVEF with LGE ≥2 segmentsadmit, CMR, monitor
lowstable or mild symptoms, LVEF ≥50%, no or minimal LGEward observation → discharge once troponin trends down
flowchart TD
    A[Chest pain / HF / arrhythmia<br/>+ troponin rise] --> B[ECG, echo, CXR<br/>troponin, NT-proBNP, CRP, CBC]
    B --> C{ACS likely?}
    C -->|yes| D[Angiography or CTCA]
    C -->|no| E{High risk?<br/>shock, VT, AV block, LVEF <40%}
    D -->|no culprit| E
    E -->|yes| F[CCU/ICU, HF and arrhythmia therapy<br/>EMB ± CMR, referral centre]
    E -->|no| G[Admit, telemetry<br/>CMR]
    G --> H{CMR}
    H -->|oedema + LGE| I[Definite myocarditis<br/>supportive care]
    H -->|negative| J[Reconsider diagnosis]
    I -->|deteriorates or no response| F
  • CMR (updated Lake Louise): T2 criterion (oedema) + T1 criterion (LGE/T1 mapping) = definite; one = possible. non-ischaemic LGE (mid-wall, subepicardial, patchy) distinguishes it from subendocardial infarct
  • endomyocardial biopsy: high-risk or haemodynamically unstable, or intermediate risk not responding to therapy — when histology (giant cell, eosinophilic, sarcoid, virus PCR) would change treatment; one negative biopsy doesn’t exclude giant cell (patchy)
  • family history in recurrent or arrhythmic presentations — myocarditis can unmask genetic cardiomyopathy (desmoplakin, ARVC)

management

all patients

  • exercise restriction until clinical remission, ≥1 month — symptoms resolved, troponin/CRP normal, ECG and CMR inflammation resolved; individualised return
  • consider beta-blocker for ≥6 months, especially with troponin rise (symptoms, arrhythmia prevention)
  • chest pain with pericardial involvement → NSAID + PPI and colchicine (prevents recurrence) → acute pericarditis
  • no routine immunosuppression with preserved LVEF

LV dysfunction or HF

  • GDMT as for HFrEF → HFrEF management; continue ≥6 months after LV recovery before considering withdrawal
  • corticosteroids may be considered if LVEF impaired and refractory to HF therapy

fulminant myocarditis

  • inotropes/vasopressors → cardiogenic shock; early Shock Team call and transfer to a centre with VA-ECMO and biopsy — recovery rate is high, so bridge early
  • IABP reasonable as first MCS step; escalate within ~1 h if perfusion doesn’t improve
  • early EMB, even on MCS; steroids for non-infectious forms
  • in-hospital survival on VA-ECMO ~60–70%; transplant/LVAD if no recovery

arrhythmia and conduction

  • AV block often reversible → temporary pacing; permanent pacemaker only if high-grade block persists → bradyarrhythmias and pacemakers
  • sustained VT in active inflammation → treat acutely; ICD decision usually deferred 3–6 months (wearable defibrillator as bridge in high-risk patients)
  • sustained poorly tolerated VT after the active phase, or sarcoid with VT or LVEF ≤35% → ICD → ventricular arrhythmias and sudden cardiac death
  • giant cell or sarcoid with VT/AV block → early ICD consideration

specific forms

formtreatment
ICI myocarditisstop ICI (rechallenge only after MDT review); pulse IV methylprednisolone within 24 h; steroid-refractory at 24–48 h → second-line immunosuppression — doses and escalation → immune checkpoint inhibitor toxicity
giant cellcombined immunosuppression (steroid + cyclosporine ± azathioprine/mycophenolate); steroid alone doesn’t prolong transplant-free survival; ~85% death or transplant at 3 years historically
eosinophilicIV steroids; treat cause (stop drug, EGPA, HES); consider anticoagulation (LV thrombus ~12%)
sarcoidprednisone ± methotrexate; FDG-PET to monitor
virus-negative lymphocytic, chronic/inflammatory CMprednisone 1 mg/kg ± azathioprine — specialist, biopsy-proven only
clozapine / drugstop drug; steroids if severe
Lymedoxycycline 100 mg BID PO if mild; ceftriaxone 2 g IV daily if severe; 14–21 days

follow-up and prognosis

  • at ≤6 months: clinical review, ECG, Holter, exercise test, echo and CMR → guides return to sport and work, residual risk
  • uncomplicated: review at 6, 12 and 24 months; complicated or residual LGE/LV dysfunction → lifelong
  • uncomplicated (chest pain, preserved LVEF): in-hospital mortality ~0%, recurrence ~5% at 1 year
  • complicated: in-hospital mortality ~8.5%, death or transplant ~18% at 5 years; fulminant ~24% mortality at 60 days
  • prognosis tracks LVEF at baseline and at 6 months; persistent LGE (especially septal) predicts VT regardless of LVEF
  • driving after VT/ICD → fitness to drive (cardiac)

Prepared 2026-10-22. Not yet verified — check every number against the sources.

Key references

Suggest a correction myocarditis